Monthly Archive:: January 2018

Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

revefenacin Treatment for Chronic Obstructive Pulmonary Disease Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease Print this page DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 …